Thymosin Alpha-1 10MG

Thymosin Alpha-1 10MG

$133.00

Thymosin Alpha-1 modulates immune function and has been researched for treating infections, respiratory disorders, hepatitis, and cancer.

66 in stock (can be backordered)

Quantity Discount / Amount Price
5 5% $126.35
10 10% $119.70
Summary
Thymosin Alpha-1 10MG$133.00
$133.00

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally occurring in the thymus gland. It is derived from a larger protein called prothymosin alpha, encoded by the PTMA gene in humans. Tα1 has long been recognized for its ability to modify, enhance, and restore immune function. As an immunomodulatory peptide, it plays crucial roles in T cell differentiation, development, and maturation. Synthetic versions of Tα1, such as thymalfasin, have been developed and approved in over 35 countries for various clinical applications, particularly in treating viral infections, immunodeficiency disorders, and as an adjunct therapy in certain cancers.

Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

Molecular Formula: C129H215N33O55

Molecular Weight: 3108.32 g/mol

CAS Number: 62304-98-7

  1. Immunomodulation: Tα1 enhances T-cell, dendritic cell, and antibody responses. It modulates cytokine and chemokine production and blocks steroid-induced apoptosis of thymocytes.
  2. Antiviral Properties: Studies have shown Tα1's efficacy in treating viral infections, particularly hepatitis B and C. It has demonstrated the ability to improve liver function and increase overall survival in hepatocellular carcinoma patients.
  3. Cancer Therapy: Tα1 has shown promise in enhancing the efficacy of cancer treatments, particularly when used in combination with chemotherapy or immunotherapy. It may help counteract the immunosuppressive side effects of conventional cancer therapies.
  4. Sepsis Treatment: Research indicates that Tα1 may be beneficial in treating sepsis by modulating the immune response and reducing inflammation.
  5. COVID-19 Application: Recent studies have explored the potential of Tα1 in treating severe COVID-19, particularly in cancer patients, due to its ability to trigger adaptive immune responses and modulate T-cell activity.

  1. Mechanism of Action: Further research is needed to fully elucidate the molecular mechanisms by which Tα1 exerts its diverse effects across different tissue types and disease states.
  2. Combination Therapies: Exploring potential synergistic effects of Tα1 with other therapeutic agents, particularly in cancer treatment and infectious diseases.
  3. Long-term Safety: Extended studies are required to assess the long-term safety profile of Tα1, especially in diverse patient populations.
  4. Expanded Clinical Applications: Investigation into Tα1's potential benefits in other immune-related disorders and as an adjunct therapy in various conditions.
  5. Optimal Dosing Regimens: Research into optimal delivery methods and dosing regimens for different conditions could enhance the therapeutic potential of Tα1.

  1. Baralt, D., et al. (2020). "Thymosin alpha 1: A comprehensive review of the literature." World Journal of Clinical Cases, 8(23), 5821-5832. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747025/
  2. Tao, N., et al. (2023). "Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application." International Journal of Molecular Sciences, 24(8), 7296. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144173/
  3. Li, J., et al. (2013). "Thymosin alpha 1: Biological activities, applications and genetic engineering production." Peptides, 46, 1-8. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115394/
  4. Costantini, C., et al. (2019). "A Reappraisal of Thymosin Alpha1 in Cancer Therapy." Frontiers in Oncology, 9, 873. [Online].
    Available: https://www.frontiersin.org/articles/10.3389/fonc.2019.00873/full
  5. ChemicalBook. (2024). "Thymosin α1 | 62304-98-7." [Online].
    Available: https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7678989.htm
  6. Costanzo, M., et al. (2021). "Thymosin α1 for prevention of severe COVID-19 in cancer patients." Pharmacological Research, 163, 105302. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874885/
Thymosin Alpha-1 represents a promising avenue for immunomodulation with potential applications in various medical fields, including infectious diseases, cancer therapy, and immune disorders. As with all peptide therapies, it is important to use Thymosin Alpha-1 under medical supervision, and its potential benefits and risks require ongoing evaluation through long-term clinical use and further research.